Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the EMA said. Alzheimer's charities say they are disappointed by the decision because thousands of people ...
Aducanumab targets the underlying cause of Alzheimer's, the most common form of dementia, rather than its symptoms. Charities have welcomed the news of a new therapy for the condition. But ...
Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...
From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Anti-amyloid-beta monoclonal antibody treatments, such as aducanumab and lecanemab, have proven to be effective in clearing ...
Medpage Today on MSN1 个月
Alzheimer's Data Withdrawn
A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...